Ramipril Supply Limit Extended to October
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor, taken by around 6 million people. It is the most commonly prescribed antihypertensive in the UK, and among the top 10 most-prescribed medications overall. It is often preferred over other drugs because its long half-life means it can be taken just once daily.The SSP was extended in May and again on 23 July.
- ▪Ramipril is an angiotensin-converting enzyme (ACE) inhibitor, taken by around 6 million people.
- ▪It is the most commonly prescribed antihypertensive in the UK, and among the top 10 most-prescribed medications overall.
- ▪It is often preferred over other drugs because its long half-life means it can be taken just once daily.The SSP was extended in May and again on 23 July.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape Medical News Headlines |
| Canonical URL | https://www.medscape.com/viewarticle/ramipril-supply-limit-extended-october-2026a1000p92?src=rss |
| Publication time | Fri, 24 Jul 2026 16:34:16 EDT |
| Retrieval time | 2026-07-25T04:44:09.253Z |
| Last seen | 2026-07-25T04:44:09.253Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | kmvcCqrcuqAp |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
The one-month limit on ramipril 1.25 mg capsule supplies has been extended until 30 October, prompting pharmacists to renew calls to be allowed to use their professional judgement to substitute an alternative product.In April, the Department of Health and Social Care (DHSC) issued a serious shortage protocol (SSP) for ramipril 1.25 mg capsules, telling pharmacies to limit supplies to one month per prescription.Around 14 million adults in the UK have high blood pressure. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor, taken by around 6 million people. It is the most commonly prescribed antihypertensive in the UK, and among the top 10 most-prescribed medications overall.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape Medical News Headlines.
Discussion
0 commentsMore from Medscape Medical News Headlines
